Drug Discovery World's Diana Turner interviewed with Dr Peter Smith, Executive Chair of Racura Oncology, following the company’s AU$34.3 million raise to advance RC220 across AML, EGFR‑mutant NSCLC and anthracycline cardioprotection.

Smith explains how Racura revived (E,E)-bisantrene (once abandoned due to solubility issues) after discovering it silences MYC by stabilising the G‑quadruplex in the MYC promoter, offering a way to tackle treatment resistance in cancers where MYC is heavily upregulated. The discussion covers Racura’s reformulation breakthrough, its Phase III plans in AML, the HARNESS‑1 trial aiming to delay osimertinib resistance, and how MYC suppression could unlock broader precision‑oncology combinations.

Read the full article here.